DataMEDS AI (MEDS) Stock Soars 87% Following Helomics Acquisition Completion

Key Takeaways

Table of Contents

DataMEDS AI (MEDS) shares jumped 87.20% to close at $1.62 following the finalized acquisition of Helomics Corp. from Axe Compute (AGPU)
The transaction carried a $1.5 million valuation, executed via common stock and an acquisition note without external debt financing
Assets obtained include Helomics’ CLIA/CAP-certified laboratory facility, complete equipment inventory, the Predictive Oncology CRO services division, and $1.5 million cash
This transaction positions DataMEDS within the $40 billion U.S. oncology diagnostics and therapeutics sector
MEDS currently maintains approximately $5 million in market capitalization and has declined 97.64% year-over-year

DataMEDS AI (NASDAQ: MEDS) experienced an 87.20% surge on Tuesday, closing at $1.62 per share after announcing the completed acquisition of Helomics Corporation from Axe Compute Inc. (NASDAQ: AGPU). Pre-market activity showed the stock climbing 66% before additional momentum carried it higher during standard trading hours.

DataMEDS AI, Inc., MEDS

The transaction’s $1.5 million total value was structured through common equity shares and an acquisition note. Notably, DataMEDS avoided assuming any external debt obligations through this purchase.

DataMEDS obtained several key assets including Helomics’ CLIA/CAP-certified clinical testing facility, complete ownership of laboratory equipment and infrastructure, the Predictive Oncology contract research organization (CRO) central laboratory services operation, plus $1.5 million in liquid capital.

Pittsburgh-based Helomics leverages artificial intelligence technology to evaluate real-world tumor information. The company provides support for pharmaceutical development and personalized cancer treatment strategies through functional precision medicine approaches.

This strategic acquisition establishes DataMEDS’ presence within the approximately $40 billion United States cancer diagnostics and treatment industry.

Moving Beyond GLP-1 and Long COVID Services

Gerald Commissiong, Interim Co-CEO of DataMEDS, explained that this transaction advances the company’s expansion into oncology services, emphasizing enhanced care access for patients in underserved rural communities. He highlighted that DataMEDS intends to broaden its portfolio beyond managing GLP-1 agonist complications and Long COVID treatment to encompass comprehensive cancer diagnostics and therapy.

Operating under DataMEDS management, Helomics aims to extend capabilities beyond molecular tumor profiling and chemosensitivity analysis. Future initiatives encompass cancer screening programs, conventional CLIA laboratory offerings, and nutritional therapy support for oncology patients.

Axe Compute CEO Chris Miglino stated the transaction framework preserves his company’s equity stake in Helomics moving forward. Axe Compute will redirect resources toward expanding its primary AI infrastructure operations.

Helomics represented the final operational business unit from Axe Compute’s prior corporate identity as Predictive Oncology Inc., preceding the company’s December 2025 rebranding.

Financial Metrics

DataMEDS maintains an approximate market capitalization of $5 million. The stock’s 52-week trading range spans from $0.82 to $75. Shares have contracted 97.64% during the trailing twelve-month period.

At publication time, MEDS registered an RSI reading of 56.10.

AGPU shares advanced 2.74% during the same trading session.

Additional transaction documentation will be submitted via Current Report on Form 8-K to the Securities and Exchange Commission.